RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA — ANDREW QUONG (FLUIDIGM CORPORATION)
Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advant
| Project title | RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA |
|---|---|
| Project number | 75N92020C00009-P00002-9999-1 |
| PI name | ANDREW QUONG |
| Institution | FLUIDIGM CORPORATION |
| Funding mechanism | N02 |
| Agency | NHLBI |
| Award amount | $8.58M |
| Fiscal year | 2021 |
| Project start | 2020-07-30T00:00:00 |
| Project end | 2021-09-30T00:00:00 |
| Abstract | Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advant |
| Key terms | <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Assay><Bioassay><Biologic Assa |
$799/mo
Try GrantRadar →